Skip to content

Translation and Validation of the COMM and ASI-SR

Translation and Validation of the COMM and ASI-SR - Instruments for Assessing Substance Use Disorder Development in a Swedish Population of Patients With Long-term Pain Treated With Opioids

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06084520
Acronym
COMMISS
Enrollment
400
Registered
2023-10-16
Start date
2023-12-01
Completion date
2026-12-31
Last updated
2024-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder, Opioid Use, Opioid Use Disorder, Pain, Chronic

Brief summary

The goal of this observational study is to translate the COMM (Current opinion misuse measure) form and validate it using the ASI-SR (Addiction severity score-self report)in a Swedish population of pain patients treated with opioids. The secondary aim is to investigate acceptability of the instrument in a Swedish population of pain patients with long-term opioid treatment (LOT). The tertiary aim is to investigate the prevalence of alcohol and illicit substance use in a Swedish population of pain patients with LOT.

Detailed description

There is no validated instrument for the assessment of early detection of substance use disorder development in swedish language. In order to address this gap, investigators plan to translate and validate the COMM questionnaire using the ASI-SR in a Swedish population of pain patients undergoing opioid treatment. In addition, study will investigate the prevalence of illicit substance use in this population and compare it to patients who are not receiving opioid treatment. The collection of material (blood) in the Uppsala Biobank for future analysis of neurobiological processes during long-term pain treatment will be performed. Phase 1: Translation of the instrument takes place according to the Patient-Reported Outcome (PRO) Consortium translation process guidelinesand according to guidelines from the company MAPI ResearchTrust, which owns the rights to use of the instrument. Phase 2: The subsequent phase entails validating the COMM instrument against the ASI-SR in a Swedish sample of patients experiencing long-term pain, in accordance with the Cosmin guidelines \[40\], and involves the following procedures. Firstly, the reliability of the COMM instrument by examining internal consistency, test-retest consistency, standard error of measurement (SEM), and conducting factor analysis with rotation in a Swedish population of patients with long-term pain andlong-term opioid treatment (LOT)will be assessed. Secondly, validity of the COMM instrument with regard to comprehensiveness, scope, user-friendliness, and predictability within this particular population will be investigated. Furthermore, investigators will assess the acceptability of the instrument among the study population. Finally, exploration of the prevalence of substance use alongside LOT in pain patients and compare it with pain patients who do not receive opioid treatment will be performed. Inclusion goal is to recruit 200 research subjects from various healthcare settings, including primary care, specialized pain care, other specialized care (e.g., Endometriosis Center), and addiction care (addiction medicine program for pain patients) for the test group. Additionally, 200 individuals are planned to be recruited from pain centers and primary care for the control group to measure prevalence rates. The control group will consist of patients with long-term pain who are not undergoing opioid treatment. Since the study involves two groups of patients with long-term pain (with and without opioid treatment), research group will inquire separately if participants are willing to provide blood samples for biomarker analysis of pain (O-link panel) and genetic analysis, which will be stored in the biobank for future research on the effects of opioids. Validation will be conducted using the results of drug and alcohol analysis from salivatests and blood. Each category, as identified by the original COMMinstrument, will be evaluated against the following instruments: 1. Symptoms and signs of drug abuse (question 1) - AUDIT, DUDIT, ASI-SR, drug and alcohol test 2. Emotional and psychiatric problems (questions 2, 5, 7, 8, 13) - ASI-SR, GAD-7, PHQ9 3. Visitor characteristics/patterns (questions 3, 12, 17) - medical record data 4. Occurrence of untrue statements (doubt/lie/untruth) and drug use (questions 4, 6, 9, 10, 11) - medical record data, drug and alcohol tests 5. Medication use and deviation from prescription (non-compliance) (questions 14, 15, 16) - medical record data, occurrence of overprescription. Pain-related questions will be assessed using the BPI-SF. In addition, research subjects will also be asked if they would like to be interviewed by a researcher in connection with their consent. Thirty of the initial research subjects who respond positively will undergo a semi-structured interview, where ease of use will be examined using the think aloud method. This involves asking subjects about their thoughts on the forms, including their understanding of the questions, language choices, and any possible negative associations. The interviews will then be reviewed using qualitative content analysis. Moreover, an extensive assessment will be undertaken, involving the input of 10 esteemed professionals in Sweden who specialize in various fields related to this subject matter, such as pain doctors, addiction medicine doctors, psychologists, behavioral scientists, and others. These experts will be approached to provide their valuable insights by responding to a set of carefully devised questions concerning the evaluation of content validity. Their estimations will serve as the fundamental basis for calculating the Content Validity Index (CVI). In order to collect and analyze the health data, information from medical records, relevant forms, and laboratory responses are compiled into a study database and then transferred to a statistics program. To ensure internal consistency and reliability, Cronbach's alpha is used, with the expectation that it will be higher than 0.70 at a significance level of p\<0.05. Additionally, the agreement between the two test occasions of COMM is assessed using the intraclass correlation coefficient (ICC). The ICC is classified as satisfactory if below 0.40, good if between 0.40-0.59, and excellent if between 0.60-0.70. The correlation between the results of COMM and the ASI-SR is examined using both the Pearson and Spearman correlation coefficients, which are calculated for the respective clusters of questions in the form. Furthermore, confirmatory factor analysis with rotation is employed to investigate the relationship between different clusters or dimensions of questions that can be identified for correlation purposes. The discriminant validity of ASI-SR composite scores and external validity measures are determined by calculating the intercorrelation matrix between COMM groups of questions, ASI-SR composite scores, and external validation measures. The minimum requirement for correlation is set at \>0.40. Statistical processing is conducted using SPSS, SAP, and Amos programs. It should be noted that the qualitative aspect of the study is not covered by the statistical plan. In terms of prevalence estimation, both the test group and the control group will be described using descriptive statistics. The occurrence of addictive drugs, non-prescribed drugs, and measures of alcohol use (PETh) during the last three weeks in both groups will be compared using a chi-square test. Odds analysis will be performed to assess secondary use of illegal substances, parallel dependence on other substances, and drugs and alcohol during the length of the study.

Interventions

DIAGNOSTIC_TESTCurrent Opioid Misuse Measure (COMM)-SWE

Patients in test group should fulfill the the COMM and the battery of validation forms as well as leave the oral fluid for illicit drugs test and whole blod for phosphatidylethanol test.

DIAGNOSTIC_TESTOral fluid drug test

Oral fluid sampling to detect drugs. Analysis with LC-HRMS

DIAGNOSTIC_TESTPETh

Alcohol use detection

DIAGNOSTIC_TESTASI-SR

Cross-validation form

DIAGNOSTIC_TESTAUDIT

Cross-validation form

DIAGNOSTIC_TESTDUDIT

Cross-validation form

DIAGNOSTIC_TESTBrief Pain Inventory - BPI

Cross-validation form

DIAGNOSTIC_TESTPatient Global Impression of Change PGIC

Cross-validation form

DIAGNOSTIC_TESTGAD-7

Cross-validation form

DIAGNOSTIC_TESTPatient Health questionnaire (PHQ9)

Cross-validation form

DIAGNOSTIC_TESTDBS - cannabis test

cross-validation form

OTHERSample of Blood for later DNA and immunological analysis in future studies

sample collection for future studies

Sponsors

The Kamprad Family Foundation for Entrepreneurship, Research & Charity
CollaboratorOTHER
Uppsala University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Intervention group: * Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week * opioid treatment for at least 1 month during last 6 months * age 18-75 years * fluent in spoken and written Swedish. Control group: * Patients with long-term, non-cancer-related pain (\>3 months) at least 3 days a week * no opioid treatment at inclusion and during last 3 months * age 18-75 years * fluent in spoken and written Swedish

Exclusion criteria

* ongoing diseases or conditions that prevents the patient from completing to the study according to the doctor's assessment * serious cognitive disorder that makes answering the questions impossible. - - ongoing or treated cancer in the last 10 years * Insufficient knowledge of Swedish

Design outcomes

Primary

MeasureTime frameDescription
COMM - Current opioid misuse version Swedish versionBaselineCOMM is based on 17 questions, all of which are answered on a 5-point Likert scale. As the original COMM instrument has identified 5 categories of questions, each area will be assessed against the following instruments: 1. Symptoms and signs of drug abuse (question 1) - AUDIT, DUDIT, ASI-SR, drug and alcohol test 2. Emotional and psychiatric problems (questions 2,5,7,8,13) - ASI-SR, GAD-7, PHQ9 3. Visitor characteristics/patterns (questions 3,12,17) - medical record data 4. Occurrence of untrue statement (doubt/lie/untruth) and drug use (questions 4,6,9,10,11) - medical record data, drug and alcohol tests

Secondary

MeasureTime frameDescription
ASI-SR Addiction severity index - short releaseBaselineThis instrument is based on interview questions that are used for addiction monitoring by calculating composite scores, mathematical score measures that are sensitive to change and that are used for follow-up and research. The scoring measures are produced according to a standardized model from the National Board of Health and Welfare (2017). Each domain is calculated in point measures.
COMM - 2nd test1 week after baselineCOMM is based on 17 questions, all of which are answered on a 5-point Likert scale. For retest consistency.
AUDIT Alcohol Use Disorder Identification TestBaselineScoring system, (0-40)where increase of the points reflects increased risk of problematic alcohol use.
BPI-Brief Pain Inventory - short formBaselineBPI-SF measures ongoing intensity and impact of pain on different areas of life (eg activity, sleep, well-being). Questions are answered in scale 0-10. From there you can calculate the indexes Pain Intensity and Pain Interference.
Patient global impression of change - PGI-CBaseline7-grade scale (-3-+3)where the lowest points indicate negative and highest points indicate positive change.
Patient Health Questionnaire PHQ9BaselineDepression Assesment scoring system, (0-15) where \<4 is no need of depression treatment, and \>15 identifies need of pharmacologic or other depression treatment
Drug detection test - salivabaselineAnalysis performs with tandem high-resolution liquid mass spectrometry (LC-HRMS) positive/negative results according to the intern cut-off standard
PETh - Phosphatidylethanol in bloodbaselineTest monitoring alcohol consumtionduring last 3 weeks monitoring. Results talking: no alcohol use \< 0.05 microg/l , moderate use 0.05-0.30, regular high. amount use \>30microg/l.
Cannabis in DBS ( Dry blood spott)baselineAnalysis performs with tandem high-resolution liquid mass spectrometry (LC-HRMS) positive/negative results according to the intern cut-off standard
Generalized anxiety disorder (GAD-7)[baseline7-items scale, Summary score (0-21), where severity of anxiety increase with more points: \<5 no anxiety, 6-10 mild, 11-16 moderate, \<17 severe
Drug Use Disorder Identification Test (DUDIT)BaselineScoring system,(0-44) where increase of the points reflects increased probability of drug abuse syndrome.

Other

MeasureTime frameDescription
Descriptive characteristics of the groupbaselineAge, sex, level of education, work status is requested in the survey, duration of treatment and pain condition and number of visits to healthcare in the last six months (specifically acute visits), diagnosis for which the preparation is prescribed, preparation and dose and actual amount prescribed in the last 6 months and any signs of overuse or problematic use For evaluating factor structure principal component analyses (PCA) .

Countries

Sweden

Contacts

Primary ContactLenka Katila, MD
lenka.katila@uu.se+46186113739
Backup ContactRolf Karlsten, PhD
rolf.karlsten@uu.se+46186113518

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026